Premium
Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis
Author(s) -
Demoly P.,
KleineTebbe J.,
Rehm D.
Publication year - 2017
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.13155
Subject(s) - house dust mite , medicine , placebo , exacerbation , sublingual immunotherapy , dust mites , mite , allergy , immunology , allergen , biology , botany , alternative medicine , pathology
Treatment with SQ (standardised quality) house dust mite sublingual tablet for 1 year resulted in a decreased probability of having an allergic rhinitis (AR) exacerbation day (from 11% [placebo] to 5% [ SQ house dust mite sublingual tablet]) and an increased probability of having a mild AR day (from 16% [placebo] to 34% [ SQ house dust mite sublingual tablet]).